Today's Rundown Bayer and Merck's vericiguat leads off virtual meeting with positive phase 3 heart failure data AstraZeneca's Farxiga shows benefit in heart failure patients regardless of prior treatment New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half Medtronic's renal denervation study returns, showing drops in stubbornly high blood pressure AstraZeneca's Brilinta taken solo is less risky than aspirin combo New Amarin analysis may explain Vascepa's heart-helping success Regeneron’s Praluent sidekick cuts cholesterol in half—even in hard-to-treat patients J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery MyoKardia's mavacamten reduces heart stress signs in targeted biomarker study Amgen's Repatha cuts cholesterol in rarely studied HIV patients Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy Edwards' TAVR safety study holds equal to open surgery after 2 years in low-risk patients 10-year coronary stent outcomes similar to bypass surgery, but less durable Featured Story | | | Saturday, March 28, 2020 After teasing positive top-line results last November, a deeper dive into Merck & Co. and Bayer’s heart failure drug vericiguat helped kick off this year’s scientific meeting of the American College of Cardiology, presented virtually as a late-breaking trial. |
|
|---|
|
Top Stories Saturday, March 28, 2020 AstraZeneca's SGLT2 diabetes med Farxiga is chugging ahead to a pioneering FDA approval in heart failure patents with or without Type 2 diabetes—a first in its class. As it awaits that nod, Farxiga has shown it can also be effective in treating heart failure patients regardless of other therapies they are receiving. Saturday, March 28, 2020 A new, late-phase analysis of cholesterol-lowering inclisiran—a PCSK9 drug picked up by Novartis through its $9.7 billion acquisition of The Medicines Company—showed it was able to cut LDL levels by 51% after nearly a year and a half of treatment. Sunday, March 29, 2020 Medtronic is back with new data finally demonstrating the effectiveness of its catheter-based ablation procedure aimed at the kidneys to help lower high blood pressure where multiple medications have failed. Monday, March 30, 2020 AstraZeneca has put a lot of resources in its aging blood thinner Brilinta, hoping to keep the anticoagulant's place in doctors' minds fresh for years to come. In a suite of new data, solo Brilinta has now shown benefit in stopping bleeding over a standard-of-care combo in patients who recently received a coronary stent. Monday, March 30, 2020 Amarin's fish-oil derivative Vascepa scored a major FDA win in December as a heart-helping add-on to statins in patients with high triglyceride levels or established cardiovascular disease. Despite the win, researchers were unsure how to explain Vascepa's underlying CV outcomes data––but now they might have an answer. Monday, March 30, 2020 Regeneron revealed last summer that its latest cholesterol fighter, evinacumab, cut “bad” cholesterol in half for patients with a rare genetic disorder. Now, in full results presented virtually at the annual meeting of the American College of Cardiology (ACC), together with the World Congress of Cardiology, the drug did even better in a group of particularly hard to treat patients. Saturday, March 28, 2020 Johnson & Johnson and Bayer's legacy blood thinner Xarelto has had a tough year with competitors picking up steam and prescriptions leveling off. But in a hard-to-treat artery disease, Xarelto just posted a new trial in recent post-surgery patients. Monday, March 30, 2020 The former Fierce 15 winner delivered new cardiac biomarker data showing its late-phase mavacamten compound can help improve signs of heart stress and injury in hypertrophic cardiomyopathy. Saturday, March 28, 2020 Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has been looking for a leg up in a wide-ranging clinical program involving dozens of trials. Now, in rarely studied HIV patients, Repatha has posted positive data in lowering cholesterol levels. Saturday, March 28, 2020 Esperion notched major back-to-back FDA wins in February with its cholesterol-busting duo Nexletol and Nexlizet. Now, with physicians largely unfamiliar with the drugs, Esperion is hoping new clinical data will help build confidence as both prepare to hit the market. Sunday, March 29, 2020 In 2019, Edwards Lifesciences presented data showing that patients undergoing less invasive transcatheter aortic valve replacement procedures performed better after one year compared to those who had open heart surgery. That study continues, and now—at the two-year mark—the data indicate that both sets of patients fare equally well when it comes to risks of stroke, hospitalization and death. Monday, March 30, 2020 In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years—as well as in cases of heart attack or stroke—between people that had received a drug-eluting stent for their blocked coronary artery compared with those who underwent standard bypass surgery. Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. |
|
|---|
|
Resources Sponsored by: Altran Our latest whitepaper explores how new technologies and AI developments are allowing businesses in the healthcare sector to keep up with patients’ heightened expectations. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Research Solutions 3 ways to save big on scientific literature access Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Outer Edge Technology To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Outer Edge Technology See why innovative BioPharma’s are partnering with Cloud Service Provider’s to design, manage and implement cloud strategies to smooth the path to FDA approval and enhance their competitive prowess. Sponsored by: Metabolon Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Medical Affairs Strategic Summit (MASS) East April 14-16, 2020 | New Brunswick, NJ BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA European Healthcare Compliance Certificate Program June 2-5, 2020 | Paris, France BIO International Convention June 8-11, 2020 | San Diego, CA U.S. Healthcare Compliance Certificate Program June 8-10, 2020 | Newark, NJ Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 